

Researching COVID to enhance recovery (RECOVER) adult study protocol: Rationale, objectives, and design

Short title: RECOVER Adult Cohort Protocol

Authors:

Leora I. Horwitz^{1*}; Tanayott Thaweethai²; Shari B. Brosnahan³; Mine S. Cicek⁴; Megan L. Fitzgerald⁵; Jason D. Goldman⁶; Rachel Hess⁷; S. L. Hodder⁸; Vanessa L. Jacoby⁹; Michael R. Jordan¹⁰; Jerry A. Krishnan¹¹; Adeyinka O. Laiyemo¹²; Torri D. Metz¹³; Lauren Nichols¹⁴; Rachel E. Patzer¹⁵; Anisha Sekar⁵; *Nora G. Singer*¹⁶; *Lauren E. Stiles*¹⁷; *Barbara S. Taylor*¹⁸; Shifa Ahmed²; Heather A. Algren¹⁹; Khamal Anglin²⁰; Lisa Aponte-Soto²¹; Hassan Ashktorab¹²; Ingrid V. Bassett²²; Brahmchetna Bedi²³; Nahid Bhadelia²⁴; Christian Bime²⁵; Marie-Abele C. Bind²; Lora J. Black²⁶; Andra L. Blomkalns²⁷; Hassan Brim²⁸; Mario Castro²⁹; James Chan²; Alexander W. Charney³⁰; Benjamin K. Chen³¹; Li Qing Chen³²; Peter Chen³³; David Chestek³⁴; Lori B. Chibnik³⁵; Dominic C. Chow³⁶; Helen Y. Chu³⁷; Rebecca G. Clifton³⁸; Shelby Collins²³; Maged M. Costantine³⁹; Sushma K. Cribbs²³; Steven G. Deeks⁴⁰; John D. Dickinson⁴¹; Sarah E. Donohue⁴²; Matthew S. Durstenfeld⁴³; Ivette F. Emery⁴⁴; Kristine M. Erlandson⁴⁵; Julio C. Facelli⁴⁶; Rachael Farah-Abraham⁴⁷; Alope V. Finn⁴⁸; Melinda S. Fischer¹⁸; Valerie J. Flaherman⁴⁹; Judes Fleurimont⁵⁰; Vivian Fonseca⁵¹; Emily J. Gallagher⁵²; Jennifer C. Gander⁵³; Maria Laura Gennaro⁵⁴; Kelly S. Gibson⁵⁵; Minjoung Go⁵⁶; Steven N. Goodman⁵⁷; Joey P. Granger⁵⁸; Frank L. Greenway⁵⁹; John W. Hafner⁶⁰; Jenny E. Han⁶¹; Michelle S. Harkins⁶²; Kristine S.P. Hauser⁶³; James R. Heath⁶⁴; Carla R. Hernandez⁶⁵; On Ho⁶⁶; Matthew K. Hoffman⁶⁷; Susan E. Hoover²⁶; Carol R. Horowitz⁶⁸; Harvey Hsu⁶⁹; Priscilla Y. Hsue⁴⁰; Brenna L. Hughes⁷⁰; Prasanna Jagannathan⁵⁶; Judith A. James⁷¹; Janice John⁷²; Sarah Jolley⁷³; S. E. Judd⁷⁴; Joy J. Juskowich⁷⁵; Diane G. Kanjilal⁷⁶; Elizabeth W. Karlson⁷⁷; Stuart D. Katz⁷⁸; J. Daniel Kelly⁴⁰; Sara W. Kelly⁷⁹; Arthur Y. Kim⁷⁶; John P. Kirwan⁸⁰; Kenneth S. Knox⁶⁹; Andre Kumar⁵⁶; Michelle F. Lamendola-Essel⁷⁸; Margaret Lanca⁸¹; Joyce K. Lee-Iannotti⁸²; R. Craig Lefebvre⁸³; Bruce D. Levy⁸⁴; Janet Y. Lin³⁴; Brian P. Logarbo, Jr.⁸⁵; Jennifer K. Logue⁸⁶; Michele T. Longo⁸⁷; Carlos A. Luciano⁸⁸; Karen Lutrick⁸⁹; Shahdi K. Malakooti⁹⁰; Gail Mallett⁹¹; Gabrielle Maranga¹; Jai G. Marathe⁹²; Vincent C. Marconi⁹³; Gailen D. Marshall⁹⁴; Christopher F. Martin⁴⁷; Jeffrey N. Martin⁹⁵; Heidi T. May⁹⁶; Grace A. McComsey⁹⁷; Dylan McDonald³⁷; Hector Mendez-Figueroa⁹⁸; Lucio Miele⁹⁹; Murray A. Mittleman¹⁰⁰; Sindhu Mohandas¹⁰¹; Christian Mouchati⁹⁰; Janet M. Mullington¹⁰²; Girish N Nadkarni¹⁰³; Erica R. Nahin⁷⁸; Robert B. Neuman¹⁰⁴; Lisa T. Newman¹⁰⁵; Amber Nguyen²; Janko Z. Nikolich¹⁰⁶; Igho Oforokun⁴⁷; Princess U. Ogbogu¹⁰⁷; Anna Palatnik¹⁰⁸; Kristy T.S. Palomares¹⁰⁹; Tanyalak Parimon³³; Samuel Parry¹¹⁰; Sairam Parthasarathy²⁵; Thomas F. Patterson¹¹¹; Ann Pearman⁹⁰; Michael J. Peluso¹¹²; Priscilla Pemu¹¹³; Christian M. Pettker¹¹⁴; Beth A. Plunkett¹¹⁵; Kristen Pogreba-Brown¹¹⁶; Athena Poppas¹¹⁷; J. Zachary Porterfield¹¹⁸; John G. Quigley¹¹⁹; Davin

K. Quinn¹²⁰; Hengameh Raissy¹²¹; Candida J. Rebello¹²²; Uma M. Reddy¹²³; Rebecca Reece⁷⁵; Harrison T. Reeder²; Franz P. Rischard¹²⁴; Johana M. Rosas⁷⁸; Clifford J. Rosen⁴⁴; Nadine G. Rouphael²³; Dwight J. Rouse¹²⁵; Adam M. Ruff²⁹; Christina Saint Jean¹; Grecio J. Sandoval³⁸; Jorge L. Santana¹²⁶; Shannon M. Schlater¹²⁷; Frank C. Scieurba¹²⁸; Caitlin Selvaggi²; Sudha Seshadri¹²⁹; Howard D. Sesso¹³⁰; Dimpy P. Shah¹³¹; Eyal Shemesh¹³²; Zaki A. Sherif¹³³; Daniel J. Shinnick²; Hyagriv N. Simhan¹³⁴; Upinder Singh¹³⁵; Amber Sowles¹³; Vignesh Subbian¹³⁶; Jun Sun¹¹; Mehul S. Suthar¹³⁷; Larissa J. Teunis¹³⁸; John M. Thorp, Jr.¹³⁹; Amberly Ticotsky⁷²; Alan T. N. Tita¹⁴⁰; Robin Tragus¹⁴¹; Katherine R. Tuttle¹⁴²; Alfredo E. Urdaneta²⁷; P. J. Utz¹³⁵; Timothy M. VanWagoner¹⁴³; Andrew Vasey⁴¹; Suzanne D. Vernon¹⁴⁴; Crystal Vidal¹; Tiffany Walker²³; Honorine D. Ward¹⁴⁵; David E. Warren¹⁴⁶; Ryan M. Weeks¹⁴⁷; Steven J. Weiner³⁸; Jordan C. Weyer¹⁴⁸; Jennifer L. Wheeler¹⁴⁸; Sidney W. Whiteheart¹⁴⁹; Zanthia Wiley⁴⁷; Natasha J. Williams¹⁵⁰; Juan P. Wisnivesky¹⁰³; John C. Wood¹⁵¹; Lynn M. Yee¹⁵²; Natalie M. Young¹⁹; Sokratis N. Zisis⁹⁷; Andrea S. Foulkes²

Affiliations:

¹ Department of Population Health, NYU Grossman School of Medicine, New York, NY, USA

² Department of Biostatistics, Massachusetts General Hospital, Boston, MA, USA

³ Division of Pulmonary Critical Care and Sleep Medicine, NYU Langone Health, New York, NY, USA

⁴ Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

⁵ Patient Led Research Collaboration on COVID-19, Washington, DC, USA

⁶ Division of Infectious Diseases, Providence Swedish Medical Center, Seattle, WA, USA

⁷ Department of Population Health Sciences and Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA

⁸ Department of Medicine, West Virginia University, Morgantown, WV, USA

⁹ Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, San Francisco, CA, USA

¹⁰ Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Medford, MA, USA

¹¹ Department of Medicine, University of Illinois Chicago, Chicago, IL, USA

¹² Department of Medicine, Howard University, Washington DC, USA

¹³ Department of Obstetrics and Gynecology, University of Utah Health, Salt Lake City, UT, USA

¹⁴ Body Politic COVID-19 Support Group, Boston, MA, USA

¹⁵ Department of Medicine and Surgery, Health Services Research Center, Emory University School of Medicine, Atlanta, GA, USA

¹⁶ Department of Medicine and Rheumatology, The MetroHealth Medical Center, Cleveland, OH, USA

¹⁷ Department of Neurology, Stony Brook University Renaissance School of Medicine, Stony Brook, NY, USA

¹⁸ Department of Medicine, Division of Infectious Diseases and Infectious Diseases, Long School of Medicine, University of Texas Health Science Center San Antonio, San Antonio, TX, USA

¹⁹ Swedish Center for Research and Innovation, Providence Swedish Medical Center, Seattle, WA, USA

²⁰ Department of Epidemiology and Biostatistics, University of California at San Francisco Institute of Global Health Sciences, San Francisco, San Francisco, CA, USA

²¹ College of Science and Health, Department of Health Sciences, DePaul University, Chicago, IL, USA

²² Medical Practice Evaluation Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

²³ Department of Medicine, Emory University, Atlanta, GA, USA

²⁴ Center for Emerging Infectious Diseases Policy and Research, Boston University School of Medicine, Boston, MA, USA

²⁵ Department of Medicine, University of Arizona, Tucson, AZ, USA

²⁶ Department of Clinical Research, Sanford Research, Sioux Falls, SD, USA

²⁷ Department of Emergency Medicine, Stanford University, Stanford, CA, USA

²⁸ Department of Pathology, Howard University, Washington, DC, USA

²⁹ Division of Pulmonary and Critical Care, University of Kansas Medical Center, Kansas City, KS, USA

³⁰ Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA

³¹ Division of Infectious Disease, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA

³² Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA

³³ Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA

³⁴ Department of Emergency Medicine, University of Illinois Chicago, Chicago, IL, USA

³⁵ Department of Neurology, Massachusetts General Hospital, Boston, MA, USA

³⁶ Department of Medicine, University of Hawaii at Manoa John A. Burns School of Medicine, Honolulu, HI, USA

³⁷ Department of Allergy & Infectious Diseases, University of Washington, Seattle, WA, USA

³⁸ Department of Biostatistics, George Washington University, Washington DC, USA

³⁹ Department of Obstetrics and Gynecology, The Ohio State University Hospital, Columbus, OH, USA

⁴⁰ Department of Medicine, University of California, San Francisco, San Francisco, CA, USA

⁴¹ Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA

⁴² Department of Research Services, University of Illinois College of Medicine, Peoria, IL, USA

⁴³ Department of Medicine, Division of Cardiology at Zuckerberg San Francisco General, University of California San Francisco, San Francisco, CA

⁴⁴ MaineHealth Institute for Research, MaineHealth, Scarborough, ME, USA

⁴⁵ Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA

⁴⁶ Department of Biomedical Informatics and Clinical and Translational Science Institute, University of Utah, Salt Lake City, UT, USA

- 47 Department of Medicine, Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA, USA
- 48 Department of Pathology, CVPPath Institute, Gaithersburg, MD, USA
- 49 Department of Pediatrics, University of California, San Francisco, San Francisco, CA, USA
- 50 Mile Square Health Center, University of Illinois Chicago, University of Illinois Chicago, IL, USA
- 51 Department of Medicine, Tulane University School of Medicine, New Orleans, LA, USA
- 52 Department of Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- 53 Center for Research and Evaluation, Kaiser Permanente of Georgia, Atlanta, GA, USA
- 54 Public Health Research Institute and Department of Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA
- 55 Department of Obstetrics and Gynecology, MetroHealth System, Cleveland, OH, USA
- 56 Department of Medicine, Stanford University, Stanford, CA, USA
- 57 Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA, USA
- 58 Department of Physiology & Biophysics, University of Mississippi Medical Center, Jackson, MS, USA
- 59 Clinical Trials, Pennington Biomedical Research Center, Baton Rouge, LA, USA
- 60 Department of Emergency Medicine, OSF Saint Francis Medical Center, Peoria, IL, USA
- 61 Department of Pulmonary and Critical Care, Emory University School of Medicine, Atlanta, GA, USA
- 62 Department of Internal Medicine University of New Mexico, Health Science Center, Albuquerque, NM, USA
- 63 Clinical Research Center, Beth Israel Deaconess Medical Center, Boston, MA, USA
- 64 Department of Bioengineering, Institute for Systems Biology, Seattle, WA, USA
- 65 Clinical Research Center, University Hospitals Cleveland Medical Center, Cleveland, OH, USA
- 66 Seattle Children's Therapeutics, Seattle, WA, USA
- 67 Department of Obstetrics and Gynecology, Christiana Care Health Services, Newark, DE, USA
- 68 Institute for Health Equity Research, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- 69 Department of Internal Medicine, University of Arizona, Phoenix, AZ, USA
- 70 Department of Obstetrics and Gynecology, Duke University, Durham, NC, USA
- 71 Department of Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA
- 72 Department of Family Medicine, Cambridge Health Alliance, Cambridge, MA, USA
- 73 Department of Pulmonary and Critical Care Medicine, University of Colorado, Aurora, CO, USA
- 74 Department of Biostatistics, University of Alabama at Birmingham, Birmingham, AL, USA
- 75 Department of Medicine, Division of Infectious Diseases, West Virginia School of Medicine, Morgantown, WV, USA
- 76 Department of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA

⁷⁷ Department of Medicine, Harvard Medical School, Boston, MA, USA

⁷⁸ Department of Medicine, NYU Langone Health, New York, NY, USA

⁷⁹ Department of Pediatrics & Department of Research Services, University of Illinois College of Medicine, Peoria, IL, USA

⁸⁰ Department Integrated Physiology and Molecular Medicine, Pennington Biomedical Research Center, Baton Rouge, LA. USA

⁸¹ Department of Psychiatry, Harvard Medical School, MA, USA

⁸² Department of Internal Medicine and Neurology, University of Arizona College of Medicine Phoenix, Phoenix, AZ, USA

⁸³ Communications Practice Area, RTI International, Research Triangle Park, NC, USA

⁸⁴ Department of Internal Medicine, Brigham and Women's Hospital, Boston, MA, USA

⁸⁵ Tulane Center for Clinical Research, Tulane University School of Medicine, New Orleans, LA, USA

⁸⁶ Department of Medicine, University of Washington, Seattle, WA, USA

⁸⁷ Tulane Center for Clinical Neurosciences, Tulane School of Medicine New Orleans, LA, USA

⁸⁸ Department of Neurology, University of Puerto Rico School of Medicine, San Juan, PR, USA

⁸⁹ Department of Family & Community Medicine, University of Arizona, College of Medicine – Tucson, AZ, USA

⁹⁰ Department of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA

⁹¹ Department of Obstetrics and Gynecology, Northwestern University, Chicago, IL, USA

⁹² Department of Medicine, Section of Infectious Diseases, Boston University Medical Center, Boston, MA, USA

⁹³ Department of Medicine, Infectious Diseases and Department of Global Health, Emory University School of Medicine, Atlanta, GA, USA

⁹⁴ Department of Medicine, University of Mississippi Medical Center, Jackson MS, USA

⁹⁵ Department of Epidemiology and Biostatistics, University of California, San Francisco; San Francisco, California, CA, USA

⁹⁶ Department of Cardiology, Intermountain Medical Center, Salt Lake City, UT, USA

⁹⁷ Department of Medicine, Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, OH, USA

⁹⁸ Department of Obstetrics, Gynecology and Reproductive Sciences, University of Texas Health Science Center at Houston, Houston, TX, USA

⁹⁹ Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA, USA

¹⁰⁰ Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA

¹⁰¹ Department of Infectious Diseases, Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA, USA

¹⁰² Department of Neurology and Sleep Medicine, Beth Israel Deaconess Medical Center, Boston, MA, USA

¹⁰³ Division of General Internal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA

¹⁰⁴ Division of Cardiology, Kaiser Permanente of Georgia, Atlanta, GA, USA

¹⁰⁵ Department of Social, Statistical and Environmental Sciences, RTI International, Research Triangle Park, NC, USA

¹⁰⁶ Department of Immunobiology, University of Arizona College of Medicine, Tucson, AZ, USA

¹⁰⁷ Division of Pediatric Allergy, Immunology, and Rheumatology, University Hospitals Rainbow Babies and Children's Hospital, Cleveland, Ohio, USA

¹⁰⁸ Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI, USA

¹⁰⁹ Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Saint Peter's University Hospital, New Brunswick, NJ, USA

¹¹⁰ Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA, USA

¹¹¹ Department of Medicine, Department of Infectious Disease, University of Texas Health, San Antonio, TX, USA

¹¹² Division of HIV, Infectious Disease, and Global Medicine, University of California, San Francisco, CA, USA

¹¹³ Department of Medicine, Morehouse School of Medicine, Atlanta, GA, USA

¹¹⁴ Department of Obstetrics, Gynecology & Reproductive Sciences, Yale School of Medicine, New Haven, CT, USA

¹¹⁵ Department of Obstetrics and Gynecology, NorthShore University Health System, Evanston, IL, USA

¹¹⁶ Department of Epidemiology and Biostatistics, University of Arizona, Tucson, AZ, USA

¹¹⁷ Division of Cardiology, Warren Alpert Medical School of Brown University, Providence RI, USA

¹¹⁸ Department of Internal Medicine, Division of Infectious Diseases, University of Kentucky, Lexington, KY, USA

¹¹⁹ Department of Medicine, Division of Hematology/Oncology, University of Illinois Chicago, Chicago, IL, USA

¹²⁰ Department of Psychiatry and Behavioral Sciences, University of New Mexico School of Medicine, Albuquerque, NM, USA

¹²¹ Department of Pediatrics, University of New Mexico, Health Sciences Center, Albuquerque, NM, USA

¹²² Department of Nutrition and Chronic Disease, Pennington Biomedical Research Center, Baton Rouge, LA, USA

¹²³ Department of Obstetrics and Gynecology, Columbia University, New York, NY, USA

¹²⁴ Department of Pulmonary and Critical Care, University of Arizona, Tucson, AZ, USA

¹²⁵ Department of Obstetrics and Gynecology, Brown University, Providence, RI, USA

¹²⁶ Department of Medicine, University of Puerto Rico, San Juan, PR, USA

¹²⁷ Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA

- ¹²⁸ Department of Medicine, Division of Pulmonary Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA
- ¹²⁹ Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Sciences Center San Antonio, San Antonio, TX, USA
- ¹³⁰ Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA, USA
- ¹³¹ Department of Population Health Sciences, Mays Cancer Center, University of Texas Health, San Antonio, TX, USA
- ¹³² Department of Pediatrics, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- ¹³³ Department of Biochemistry & Molecular Biology, Howard University College of Medicine, Washington DC, USA
- ¹³⁴ Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- ¹³⁵ Department of Internal Medicine, Stanford University, Stanford, CA, USA
- ¹³⁶ Department of Biomedical Engineering, Department of Systems and Industrial Engineering, University of Arizona College of Engineering, Tucson, AZ, USA
- ¹³⁷ Department of Pediatrics; Emory Vaccine Center, Emory University, Atlanta, GA, USA
- ¹³⁸ Health Services Research Center, Emory University, Atlanta, GA, USA
- ¹³⁹ Department of Obstetrics and Gynecology, University of North Carolina Chapel Hill, Chapel Hill, NC, USA
- ¹⁴⁰ Department of Obstetrics and Gynecology and Center for Women's Reproductive Health, University of Alabama at Birmingham, Birmingham, AL, USA
- ¹⁴¹ Department of Medicine, University of Texas Health Science Center, San Antonio, TX, USA
- ¹⁴² Department of Medicine, Division of Nephrology, University of Washington School of Medicine, Spokane, WA, USA
- ¹⁴³ Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
- ¹⁴⁴ Department of Research, Bateman Horne Center, Salt Lake City, UT, USA
- ¹⁴⁵ Department of Medicine, Tufts Medical Center, Boston, MA, USA
- ¹⁴⁶ Department of Neurological Sciences, University of Nebraska Medical Center, Omaha, NE, USA
- ¹⁴⁷ Department of Microbiology, Immunology, and Molecular Genetics, University of Kentucky, Lexington, KY, USA
- ¹⁴⁸ Center for Individualized Medicine, Mayo Clinic, Rochester, MN, USA
- ¹⁴⁹ Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, KY, USA
- ¹⁵⁰ Institute for Excellence in Health Equity, NYU Grossman School of Medicine, New York, NY, USA
- ¹⁵¹ Department of Pediatrics and Radiology, Children's Hospital of Los Angeles, Los Angeles, CA, USA
- ¹⁵² Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

* *Corresponding author*

Email: Leora.Horwitz@nyulangone.org (LH)

^Membership of the RECOVER Initiative is provided in the Supporting Information.

Registration: NCT05172024

Abstract

Importance: SARS-CoV-2 infection can result in ongoing, relapsing, or new symptoms or other health effects after the acute phase of infection; termed post-acute sequelae of SARS-CoV-2 infection (PASC), or long COVID. The characteristics, prevalence, trajectory and mechanisms of PASC are ill-defined. The objectives of the Researching COVID to Enhance Recovery (RECOVER) Multi-site Observational Study of PASC in Adults (RECOVER-Adult) are to: (1) characterize PASC prevalence; (2) characterize the symptoms, organ dysfunction, natural history, and distinct phenotypes of PASC; (3) identify demographic, social and clinical risk factors for PASC onset and recovery; and (4) define the biological mechanisms underlying PASC pathogenesis.

Methods: RECOVER-Adult is a combined prospective/retrospective cohort currently planned to enroll 14,880 adults aged ≥ 18 years. Eligible participants either must meet WHO criteria for suspected, probable, or confirmed infection; or must have evidence of no prior infection. Recruitment occurs at 86 sites in 33 U.S. states, Washington, DC and Puerto Rico, via facility- and community-based outreach. Participants complete quarterly questionnaires about symptoms, social determinants, vaccination status, and interim SARS-CoV-2 infections. In addition, participants contribute biospecimens and undergo physical and laboratory examinations at approximately 0, 90 and 180 days from infection or negative test date, and yearly thereafter. Some participants undergo additional testing based on specific criteria or random sampling. Patient representatives provide input on all study processes. The primary study outcome is onset of PASC, measured by signs and symptoms. A paradigm for identifying PASC cases will be

defined and updated using supervised and unsupervised learning approaches with cross-validation. Logistic regression and proportional hazards regression will be conducted to investigate associations between risk factors, onset, and resolution of PASC symptoms.

Discussion: RECOVER-Adult is the first national, prospective, longitudinal cohort of PASC among US adults. Results of this study are intended to inform public health, spur clinical trials, and expand treatment options.

Introduction

Hundreds of millions of people worldwide have been infected with the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2).[1] Many have experienced ongoing, relapsing, or new symptoms or other health effects occurring after the acute phase of infection, termed post-acute sequelae of SARS-CoV-2 infection (PASC), or long COVID. While more than 200 symptoms have been associated with PASC,[2] there are no agreed upon criteria for the diagnosis of PASC, and estimates of PASC incidence and prevalence vary widely.[3-9]

The pathophysiology underlying PASC remains incompletely understood.[10, 11] Various mechanisms have been proposed, including viral persistence,[12-17] microvascular clotting and platelet dysregulation,[18-21] tissue damage from initial infection,[22, 23] inflammation and immune dysregulation,[17, 24-31] reactivation of other latent viral infections (e.g., Epstein-Barr virus),[17, 32, 33] microbial translocation and dysbiosis,[34, 35] and/or impacts of pandemic-related disruptions on health.[36-38] Further characterization of PASC clinical manifestations and underlying pathophysiologic mechanisms could facilitate identification and investigation of preventive and therapeutic interventions.

Materials and Methods

Objectives

The National Institutes of Health (NIH) initiative “Researching COVID to Enhance Recovery (RECOVER) Multi-site Observational Study of Post-Acute Sequelae of SARS-CoV-2 Infection in Adults” (RECOVER-Adult) is intended to: (1) characterize the incidence and prevalence of PASC; (2) characterize the spectrum of clinical symptoms, subclinical organ dysfunction, natural history, and distinct phenotypes identified as PASC; (3) identify demographic, social determinants of health (SDoH), and clinical risk factors for PASC and PASC recovery, and (4) define the biological mechanisms underlying pathogenesis of PASC. This report describes the study design of the RECOVER-Adult study.

Study Design

RECOVER is an ambidirectional (combined retrospective and prospective) longitudinal cohort study that includes people infected or uninfected with SARS-CoV-2. Participants may be enrolled at the time of SARS-CoV-2 infection or a negative test (for uninfected group) and followed prospectively; or, may be enrolled after SARS-CoV-2 infection or a negative test, asked retrospectively about symptoms since infection or a negative test, and then followed prospectively. Participants may be followed until October 2025. An embedded cohort study of pregnant people will provide longitudinal follow-up of the birthing parent and offspring. The protocol for the pregnancy cohort is reported separately [39]. In addition, a series of nested case-control studies will be performed among participants with and without select symptoms or

findings, who will undergo more intensive radiographic imaging, physiologic assessment, and tissue collection.

Protocol development

The protocol was developed and refined in a collaborative process involving site and core investigators, patient representatives and caregivers, and NIH staff (see **S1 Fig** for timeline and details). Patient representatives were recruited from COVID advocacy organizations such as the Patient-Led Research Collaborative, Survivor Corps, and Long COVID Families; patient organizations with expertise in post-viral syndromes; grass-roots activist organizations; and through nominations by enrolling sites. All patient representatives were compensated for their time. Refinements to the protocol continue to be made in response to participant and site feedback, new scientific evidence, and interim results.

Study organizational structure and study management

The study infrastructure includes four cores: (1) the Clinical Science Core (CSC) at New York University (NYU) Grossman School of Medicine oversees study sites and provides scientific leadership in collaboration with the site Principal Investigators, (2) the Data Resource Core (DRC) at Massachusetts General Hospital and Brigham and Women's Hospital provides scientific and statistical leadership, and handles data management and storage, (3) the PASC Biorepository Core (PBC) at Mayo Clinic manages biospecimens obtained from study sites, and (4) the Administrative Coordinating Center (ACC) at RTI International (RTI) provides operational and administrative support; collectively these form the Core Operations Group. The four cores are supported by six Oversight Committees that oversee RECOVER-wide activities

including publications, ancillary studies, clinical trial interventions selection, quality assurance, and study design. Twelve pathobiology task forces provide content-specific input. All RECOVER cohort studies receive inputs from the National Community Engagement Group composed of patient and community representatives; and are overseen by a Steering Committee composed of core and hub principal investigators, patient representatives and NIH program leadership; an Executive Committee composed of NIH Institute leaders, patient representatives and other federal leadership; and an Observational Study Monitoring Board (OSMB) (S2 Fig).[40]

Study setting and participating sites

RECOVER-Adult is designed as a hub and spoke model, with 16 hubs collectively overseeing 86 enrolling sites in the United States (U.S.) located in 33 states plus Washington, DC and Puerto Rico (S1 Table). Enrolling sites include hospitals, health centers, and community organizations drawing participants primarily from their surrounding communities. Two sites are mobile health vans enrolling in rural communities far from health centers. One hub is enrolling participants remotely across the country, with study procedures conducted through home visits and biospecimen collection at local laboratories.

Eligibility Criteria

Participants are eligible for RECOVER if they are at least 18 years old, have reached the age of majority in their state of residence, are not incarcerated, and are not terminally ill. Individuals with or without history of SARS-CoV-2 infection are eligible. Infected individuals must have

suspected, probable, or confirmed SARS-CoV-2 infection as defined by World Health Organization (WHO) criteria[41] (see **Table 1**), or positive SARS-CoV-2 infection-specific antibody testing. Uninfected individuals must not meet any WHO criteria for infection and must have a documented negative SARS-CoV-2 nucleic acid and antibody test result (**Table 1**).

Table 1: Definition of infected and uninfected categories used in RECOVER-Adult.

Changes from WHO definition are indicated in italics.

WHO category	Criteria
Suspected	<p>Acute onset of fever and cough OR acute onset of any three of more of the following signs or symptoms: fever, cough, general weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, anorexia/nausea/vomiting, diarrhea, altered mental status.</p> <p>AND at least one of:</p> <ol style="list-style-type: none"> 1. Residing or working in an area with a high risk of transmission of virus: closed residential settings, humanitarian settings such as camp and camp-like settings for displaced persons; anytime within the 14 days before symptom onset; OR 2. Residing or travel to an area with community transmission* anytime within the 14 days before symptom onset; OR 3. Working in any health care setting, including within health facilities and within households or within the community; anytime within the 14 days before symptom onset. <p><i>AND</i> <i>Did not have a negative test for SARS-CoV-2 at the time of suspected infection.</i></p>
	<p>Severe acute respiratory illness: acute respiratory infection with history of fever or measured fever of $\geq 38^{\circ}\text{C}$; and cough; with onset within the last 10 days; and requires hospitalization</p> <p><i>AND</i> <i>Did not have a negative test for SARS-CoV-2 at the time of suspected infection.</i></p>
	<p>A positive SARS-CoV-2 Antigen-RDT who is asymptomatic <i>or meets some but not all clinical or epidemiologic criteria</i></p> <p><i>AND</i></p>

WHO category	Criteria
	<i>Did not have a negative test for SARS-CoV-2 at the time of suspected infection.</i>
Probable	A patient who meets clinical criteria for suspected SARS-CoV-2 AND is a contact of a probable or confirmed case or linked to a COVID-19 cluster <i>AND</i> <i>Did not have a negative test for SARS-CoV-2 at the time of suspected infection.</i>
	A patient who meets clinical criteria for suspected SARS-CoV-2 AND has chest imaging showing findings suggestive of COVID-19 disease <i>AND</i> <i>Did not have a negative test for SARS-CoV-2 at the time of suspected infection.</i>
	A person with recent onset of anosmia (loss of smell) or ageusia (loss of taste) in the absence of any other identified cause <i>AND</i> <i>Did not have a negative test for SARS-CoV-2 at the time of suspected infection.</i>
Confirmed	Any person with a positive Nucleic Acid Amplification Test (NAAT)
	Any person with a positive SARS-CoV-2 Antigen-RDT (<i>including home-administered rapid test</i>) AND meeting either the probable case definition or one of the first two suspected criteria
	An asymptomatic person with a positive SARS-CoV-2 Antigen-RDT (including home-administered rapid test) who is a contact of a probable or confirmed case
	<i>Any person with a positive SARS-CoV-2 nucleocapsid protein antibody test OR a positive SARS-CoV-2 spike protein antibody test IF not vaccinated</i>
Uninfected	Does not meet WHO criteria for a suspected, probable, or confirmed case of SARS-CoV-2 infection <i>AND</i> Has negative NAAT SARS-CoV-2 testing from a respiratory specimen performed at the time of enrollment/screening <i>AND</i> Has a negative SARS-CoV-2 nucleocapsid protein antibody and spike protein antibody test (if not vaccinated) performed at the time of enrollment <i>AND</i> Lives in the same communities or recruited from the same sources as those in the SARS-CoV-2 infected cohort

Individuals who were pregnant at the time of a SARS-CoV-2 infection and had a live birth, or who are pregnant at the time of enrollment in RECOVER, are only eligible to enroll in the

pregnancy cohort of the adult study. Their offspring are eligible for enrollment into the congenital exposure cohort of the RECOVER pediatric study. Individuals who were pregnant at the time of a SARS-CoV-2 infection and had a pregnancy loss or termination prior to 20 weeks' gestation, are eligible to enroll in either the pregnancy or the adult main cohort.

Sample size

Sample size determinations were performed for both aggregate and subgroup analyses based on characteristics such as age, sex, race/ethnicity, pregnancy, and vaccination status. The current version of the protocol targets enrollment of 12,200 participants with history of SARS-CoV-2 infection and 2,680 participants without history of SARS-CoV-2 infection (total of 14,880).

Sample size targets are further specified by duration of time between infection (or negative test) and enrollment, and by pregnancy status (**Table 2**). Based on 90% power and a type-1 error rate of 0.01, the minimum detectable effect size for the difference in risk of PASC or a PASC symptom between participants with and without infection is 3.1% (6.4% in a 25% subgroup), assuming the risk among participants without infection is 15%. When restricting to acute infected and uninfected participants only, the minimum detectable risk difference is 4.7% (10.0% in a 25% subgroup). In logistic regression analyses investigating whether an infected participant develops PASC, the minimum detectable odds ratio for a risk factor is 1.22 (1.46 in a 25% subgroup), assuming 25% of all infected participants develop PASC and that the risk factor prevalence among participants who do not develop PASC is 20%. Finally, assuming that 50% of infected participants who develop PASC recover from it during follow-up, the minimum detectable odds ratio for the association between a risk factor and recovering from PASC is 1.40

(1.90 in a 25% subgroup), assuming the risk factor has 20% prevalence among participants who do not recover from PASC.

Table 2: Sample size targets, by enrollment category

Enrollment category	Target sample size, by subgroup	Target sample size, by time since infection
Infected, enrolled within 30 days of infection, not pregnant (“acute” infected)	4,714	5,000
Infected, enrolled within 30 days of infection, pregnant at time of infection (“acute” infected)	286	
Infected, enrolled >30 days after infection, not pregnant (“post-acute” infected)	5,619	7,200
Infected, enrolled >30 days after infection, pregnant at time of infection (“post-acute” infected)	1,581	
Uninfected, enrolled within 30 days of negative test, not pregnant (“acute” uninfected)	1,141	1,200
Uninfected, enrolled within 30 days of negative test, pregnant (“acute” uninfected)	59	
Uninfected, enrolled >30 days from negative test, not pregnant (“post-acute” uninfected)	1,106	1,480
Uninfected, enrolled >30 days from negative test, pregnant (“post-acute” uninfected)	374	

Sample size targets for race/ethnicity are intended to match the distribution of SARS-CoV-2 infection in the U.S. as of June 2021: 16% non-Hispanic Black; 27% Hispanic, 4% non-Hispanic Asian, American Indian/Alaska Native or Native Hawaiian/Other Pacific Islander; and 53% non-Hispanic White.[42]

Recruitment

Participants are recruited through outreach to patients cared for at the enrolling site, community outreach, use of public health test lists, and self-referrals from the RECOVER website (<https://recovercovid.org>). For participants without SARS-CoV-2 infection, sites are asked to draw from similar communities, demographics, and sites of care as those recruiting infected participants. Enrollment is tracked by enrollment category, race/ethnicity, sex, residence in rural or medically underserved areas, hospitalization status at time of initial infection, and referral source to allow for real time adjustments in enrollment to match protocol targets.

Assessments

The RECOVER-Adult schedule of assessments includes: surveys, collection of biologic specimens, physical examinations, laboratory tests, radiologic studies, and invasive procedures to measure study outcomes. The schedule starts at the time of first infection or at the negative test date (“index date”); follow-up visits are conducted at 90-day intervals for a maximum of 4 years. All participants undergo the same assessments at baseline enrollment. Thereafter, participants follow the assessment schedule corresponding to the appropriate time point relative to the index date. For example, participants who are enrolled 90 days after infection follow the 180-day assessment schedule at their first follow-up visit (**Figure**). Participants may remain in the study if they have missed a visit; after three missed visits they may be considered lost to follow-up, in which case no further information is obtained.

Figure: Schedule of assessments

Surveys

Participants complete surveys at 90-day intervals throughout the study. On enrollment, data are collected on demographics, SDoH, disability, characteristics of the initial SARS-CoV-2 infection (if applicable), pregnancy (if applicable), vaccination status, comorbidities, medications, and PASC symptoms. Subsequently, at 90-day intervals, data are collected on interim infections, time-varying social determinants, vaccinations, comorbidities, medications and symptoms. The PASC symptom survey was developed for RECOVER and includes an overall quality of life instrument (PROMIS-10) and screening for core symptoms (43 for biological males and 46 for biological females) drawn from existing literature plus input from patient representatives and investigators. Questions about depression, anxiety, post-traumatic stress disorder (PTSD), and grief are also included. Report of a symptom may trigger additional questions about that symptom. Wherever possible, pre-existing validated survey instruments are used. Details of survey instruments can be found at <https://recovercovid.org/protocols> and in **S2 Table**.

In-person assessments

Office-based assessments are performed on all participants at enrollment, at 180 days after index date, and then at yearly increments thereafter. These include: height, weight, waist circumference, seated vitals (heart rate, blood pressure, oxygen saturation), 30 second sit-to-stand, and a 10 minute active stand test during which heart rate and blood pressure are measured at 1, 3, 5 and 10 minute intervals (**S3 Table**).

Laboratory assessments

A core set of laboratory studies are obtained on all participants at enrollment, at 90 and 180 days after the index date (**S3 Table**). After 180 days, abnormal laboratory tests from the most recent prior visit are repeated annually. At enrollment only, participants enrolled as uninfected

undergo SARS-CoV-2 PCR testing and SARS-CoV-2 antibody testing (nucleocapsid for all, and spike only for unvaccinated). These core studies are performed at each site in Clinical Laboratory Improvement Amendments of 1988 (CLIA)-certified laboratories.

Biospecimens

At enrollment, at 90 and 180 days after the index date, and then annually, participants are asked to provide blood and nasopharyngeal/nasal swab biospecimens for storage (**Table 3**). Saliva is collected once upon enrollment for genetic analysis. Urine and stool are collected biannually. Biospecimens are not collected from participants who decline use of samples for future research.

Table 3: Tier 1 Biospecimen Collection and Processing Summary

Collected Specimen	Quantity	Biobanked Specimen Type	Number of Aliquots	Aliquot Volume	Processing
Nasopharyngeal or nasal swab*	1	Nasal Cells	NA	1	Processed locally within 1 hour; frozen to -90°C to -65°C; batch shipped on dry ice
Blood in serum separator tube	2 x 8.5 ml	Serum	10	1 ml	
Blood in cell preparation tube (CPT)**	4 x 8 ml	Peripheral Blood Mononuclear Cells (PBMCs)	8 x PBMCs (target cell count minimum 5 million cells/mL)	1 ml	Centrifuged locally, refrigerated, shipped at refrigerated temperature on day of collection
Blood in sodium citrate tube**	2 x 2.7 ml	Plasma	2	1 ml	Processed locally within 1 hour; frozen to -90°C to -65°C; batch shipped on dry ice

Blood in ethylenediaminetetraacetic acid (EDTA) tube**	1 x 10 ml	Plasma White blood cells***	4 1	1 ml	Refrigerated, shipped at refrigerated temperature on day of collection
Blood in PAXgene-RNA tube	1 x 2.5 ml	Whole blood	1	2.5 ml	
Urine in no additive tube	1 x 10 ml	Urine supernatant	8	1 ml	
Saliva in Oragene OGR-600***	1 x 2 ml	Saliva	1	2 ml	
Stool	1 x 25 ml	Stool	1	25 ml	Directly sent by participant

* As of June 29, 2022, nasopharyngeal swab changed to nasal swab

** As of protocol v6.0, added sodium citrate and EDTA tubes and CPT reduced to 2 cell preparation tubes.

*** Not collected in those who decline genetic testing

Triggered testing

Participants with infection experiencing specific symptoms or having abnormal study assessments may be eligible for additional assessments, each of which is triggered by qualifying criteria. In addition, participants with and without infection are randomly selected to complete additional assessments for comparison. These assessments are divided into Tier 2 and Tier 3 assessments. Tier 2 assessments are anticipated to be completed by approximately 30% of participants per assessment, and may be repeated yearly if abnormal (**S4 Table**). Tier 3 assessments are more invasive and/or burdensome, and are anticipated to be completed by not more than 20% of participants per assessment. Tier 3 assessments with more than minimal risk can only be performed once (**S5 Table**). Participants are eligible to begin Tier 2 and Tier 3 testing 90 to 180 days after index date, depending on the assessment. Individuals who are pregnant, 3-months postpartum or breastfeeding are ineligible for some of the assessments.

Tier 2 and 3 assessments include additional surveys, blood tests, clinical examinations, imaging, and procedures. Specialized blood tests are run by a central laboratory (ARUP Laboratories, Salt Lake City, Utah) for consistency. Imaging is acquired via pragmatic standard clinical protocols to maximize testing availability across sites. Several of the imaging studies are overseen by reading centers charged with protocol development, quality assurance/control, and certifying performance sites, in addition to centralized review of a portion of studies. DICOM images are uploaded and shared using specialized cloud-based image storage software provided by Ambra Health. Clinical examinations and procedures are performed by clinically certified personnel at each site following standard clinical protocols.

Data collection and management

Study data are collected by sites and entered into a centralized REDCap (Research Electronic Data Capture) database hosted by the DRC in a Federal Information Security Modernization Act moderate environment.[43] REDCap includes data validation and audit capabilities.[44, 45] Protected health information in the central REDCap database is limited to zip code and birthdate. Automated queries are generated by the DRC for missing or implausible data and sent to sites for near real-time correction. Monthly study monitoring reports are provided to sites to optimize fidelity to protocol. Periodic audits are conducted independent of the site investigators and sponsor.

Outcomes

The primary endpoints of this study are the presence of composite incident or prevalent PASC symptoms and progression of PASC; since there is not yet an agreed-upon definition of PASC, a working definition will be developed as part of the study (see statistical analysis). Secondary

endpoints include recovery trajectories from SARS-CoV-2 infection, documentation of organ injury, and incident clinical diagnoses.

Statistical analysis

Point prevalence, defined as the proportion of participants reporting a symptom at a given follow-up time point among those remaining in RECOVER, will be calculated for participants with and without infection separately. Odds ratios (ORs) adjusted for demographic factors will be reported. Machine learning approaches will be used to select combinations of symptoms among the 40+ included in the symptom survey (i.e., variable selection) that differentiate participants with and without a history of infection [46]. Prevalent symptoms and select severity scores will be used as input to the model. Balancing weights will be applied to account for any differences between infected and uninfected participants [47]. Analyses will be iteratively refined as new data modalities (e.g. laboratory, radiology and other Tier 2/3 tests) and additional longitudinal assessments become available. Within PASC positive individuals, consensus clustering will be applied to identify PASC subgroups.[48]

Logistic regression analyses will be conducted to investigate associations between clinical factors, demographics, and SDoH, and the cumulative incidence of PASC among participants with infection. Multinomial regression models will also be used to investigate specific associations between these risk factors and PASC subgroups. A Cox proportional hazards regression will be fitted to model the hazard of developing PASC given the risk factors. A Fine-Gray model for the sub-distributional hazard of developing each PASC subgroups, accounting for the competing and semi-competing risks of each sub-phenotype as well as study dropout as a censoring event, will be fit among infected participants to estimate the association between risk

factors and the hazard of each PASC subgroups.[49] Additional strategies that account for time-varying covariates (e.g., vaccination status, pharmaceutical or clinical interventions) will be considered.[50]

A Cox proportional hazard model will model PASC resolution, defined based on longitudinal assessments, to evaluate associations with baseline factors, including markers of illness severity during the acute phase of infection. Point estimates and 95% Wald confidence intervals will be estimated for each risk factor and a large-sample score test will be conducted to test against the null hypothesis that the hazard of resolution is independently associated with each risk factor.

Observational Study Monitoring Board

The RECOVER OSMB appointed by the NIH provides data and safety oversight, meeting at least twice annually. The purpose of the OSMB is to assure independent review of unreasonable risk exposure because of study participation, monitor study progress and integrity, and advise on significant protocol modifications. The OSMB is composed of experts in longitudinal studies, manifestations of COVID-19, biostatistics and bioethics, and patient/caregiver representatives. As RECOVER-Adult does not involve any interventions, early stopping rules for efficacy or futility are not indicated.

Major changes to the protocol

A planned flexible study design allows modifications to PASC case definition, tiered phenotyping assessments, comparator groups, and statistical plan after study initiation to

optimize public health impact without undermining validity and integrity of study findings.

Table 4 lists key modifications to the protocol to date.

Table 4: Selected, key protocol modifications since initial approval

Protocol version	Date of approval	Major changes	Participants enrolled at time of modification
1.0	9/16/2021	Original release	0
1.1	10/08/2021	Additions to comorbidity form to align with NeuroCOVID Databank Orthostatic test changed to active stand test	0
2.0	10/18/2021	Coagulation panel, urinalysis, SARS-CoV-2 PCR (uninfected) added to Tier 1 Mini International Neuropsychiatric Interview, adrenocorticotrophic hormone, morning cortisol, hepatitis B and C, renal ultrasound added to Tier 2 Electrocardiogram, D-dimer, troponin, NT-pro BNP moved from Tier 2 to Tier 1 Tilt table testing, cardiovagal innervation testing, catecholamine testing moved from Tier 2 to Tier 3 Ear-nose-throat exam, lung plethysmography, dual energy chest CT moved from Tier 3 to Tier 2 Parathyroid hormone, gamma-glutamyl transferase, anti-phospholipid antibody, CT pulmonary angiography, ventilation/perfusion scan, MRI spine, abdominal CT removed from protocol	0
3.0	12/01/2021	Clarified inclusion criteria to include patients who have positive SARS-Cov-2 infection-specific antibody testing Added incarceration as an exclusion criterion. Added an opt-in for future genetic testing Removed procalcitonin and moved electrocardiogram from Tier 1 back to Tier 2 Added Anti-Mullerian hormone.	30

Protocol version	Date of approval	Major changes	Participants enrolled at time of modification
4.0	01/27/2022	Added one-time off schedule visit during on-study infection Removed option to return research lab results	399
5.0	03/22/2022	Updated the recruitment window from 24 to 36 months since first infection Added that uninfected pregnant individuals begin study schedule on delivery date Added that women <3 months postpartum can not have any tests that pregnant women can not have Specified methylmalonic acid to be drawn with serum B12	1,474
6.0	8/11/2022	Revised the earliest date of possible infection from March to January, 2020 Removed lung plethysmography Removed 15% cap on self-referral participants Changed study schedule to start at time of acute reinfection (enrollment) for previously infected participants enrolling during an acute infection Reduced the number of cell preparation tubes for collection and replaced with sodium citrate and EDTA tubes for plasma Moved anti-nuclear antibody, anti-cyclic citrullinated peptide antibodies, rheumatoid factor, Epstein Barr virus testing to Tier 2	7,698
7.0	12/15/2022	Added collection of tears as a biospecimen Added section on the mobile health platform	11,602
8.0	Pending	Reduced target N of acute infected enrollees from 7,800 to 5,000 given higher than expected PASC rates	

Data sharing and dissemination

Scientific data will be de-identified and shared pursuant to the NIH policy for Data Management and Sharing policy.[51] The RECOVER Ancillary Study Oversight Committee and Biospecimen Access Committee govern access to data and biospecimens for ancillary studies. Study results will be disseminated via scientific publication, presentation at national meetings, public-facing webinars, community briefings, RECOVER newsletters, social media, and other means of communication to both scientific and lay audiences. Additionally, results of all tests performed in CLIA-certified laboratories or read by clinically-certified personnel are returned to study participants.[52] Tests performed in research laboratories that are not CLIA-certified are not returned to participants, following federal regulations.

Ethics

The study was approved by the NYU Grossman School of Medicine Institutional Review Board (IRB), which serves as the single IRB for the majority of the study sites. A few pre-existing consortia use their own IRBs through an exemption granted by the NIH. All participants provide signed, informed consent to participate in the main protocol. Participants are reconsented if there are major changes to the study design or to anticipated risks. For high-risk Tier 3 procedures, a separate procedure-specific consent is obtained prior to the procedure.

Discussion

The overall goal of RECOVER is to rapidly improve understanding of, and ability to predict, treat, and prevent PASC. RECOVER-Adult's large sample size and breadth of representation

across geographic region, age, sex, race/ethnicity and other SDoH and pregnancy status are expected to produce broadly applicable and actionable results and support numerous subgroup analyses. Additionally, nested case-control studies will occur among participants with certain PASC phenotypes who have triggered assessments. RECOVER-Adult includes numerous strengths. Participants include many uninfected and asymptomatic infected individuals for comparison that is often missing from other large studies.[11, 53-56] All participants are followed prospectively from time of enrollment, allowing longitudinal analyses of disease trajectory. By contrast, most studies to date have been single time point assessments or serial cross-sectional studies.[3-9, 57] Acute participants enrolled at the time of first infection will provide a prospective estimate of PASC rates that is less biased than the most studies, which have enrolled subjects after PASC status is known.[3-9] The strong focus on patient-reported symptom outcomes allows capture of a broader range of sequelae than studies relying on electronic health records or claims data.[53, 58-62] The adaptive nature of the protocol allows for rapid responsiveness to new discoveries and changes in the nature of the pandemic. The extensive biospecimen collection and clinical, laboratory, and radiology assessments will generate a wealth of deep phenotyping data that can be used for pathophysiologic analyses. Finally, multi-omics analyses are proposed and have potential to provide molecular mechanistic insights into the pathophysiology of PASC.

RECOVER-Adult is also unique in the extent to which patients experiencing PASC and representatives from patient advocacy communities contributed to the protocol's development and ongoing operations. For example, the PASC symptom survey was drawn in part from lists of symptoms generated by members of the patient community,[2] allowing measurement of symptoms overlooked by other studies, including post-exertional malaise and menstrual cycle

changes. At the urging of patient representatives, participants with a clinical diagnosis of COVID were included even without a positive test history, to permit inclusion of individuals affected in the earliest stages of the pandemic when testing was not widely available. Among the many other significant design aspects credited to input from patient representatives are: wording of the consent document, including clinical assessments specific to dysautonomia, sharing clinically certified lab results with participants, ensuring accommodations for participants with myalgic encephalomyelitis/chronic fatigue syndrome, and selection of SDoH instruments.

In summary, RECOVER-Adult is a large, national, longitudinal, retrospective and prospective cohort that will answer key questions about the epidemiology and pathophysiology of PASC. Results will support clinical trial development by defining PASC and sub-phenotypes, natural history, risk factors, biomarkers, and mechanistic pathways for potential therapeutic targets. Results of this study will also inform public health efforts, prevention, and clinical care.

Acknowledgements

We would like to thank the National Community Engagement Group (NCEG), all patient, caregiver and community representatives, and all the participants enrolled in the RECOVER initiative.

References

1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard 2023 [cited 2023 9 March]. Available from: <https://covid19.who.int/>.
2. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. *EClinicalMedicine*. 2021;38:101019. Epub 20210715. doi: 10.1016/j.eclinm.2021.101019. PubMed PMID: 34308300; PubMed Central PMCID: PMC8280690.
3. Groff D, Sun A, Ssentongo AE, Ba DM, Parsons N, Poudel GR, et al. Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: A Systematic Review. *JAMA Netw Open*. 2021;4(10):e2128568. Epub 20211001. doi: 10.1001/jamanetworkopen.2021.28568. PubMed PMID: 34643720; PubMed Central PMCID: PMC8515212.
4. Matt Bosworth PP, Daniel Ayoubkhani. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 2 February 2023: Office for National Statistics, United Kingdom; 2023 [cited 2023 3 Feb 2023]. Available from: <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/latest>.
5. Chen C, Hauptert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global Prevalence of Post-Coronavirus Disease 2019 (COVID-19) Condition or Long COVID: A Meta-Analysis and Systematic Review. *J Infect Dis*. 2022;226(9):1593-607. Epub 2022/04/17. doi: 10.1093/infdis/jiac136. PubMed PMID: 35429399; PubMed Central PMCID: PMC9047189.
6. Wulf Hanson S, Abbafati C, Aerts JG, Al-Aly Z, Ashbaugh C, Ballouz T, et al. A global systematic analysis of the occurrence, severity, and recovery pattern of long COVID in 2020 and 2021. *medRxiv*. 2022. Epub 2022/06/07. doi: 10.1101/2022.05.26.22275532. PubMed PMID: 35664995; PubMed Central PMCID: PMC9164454.
7. O'Mahoney LL, Routen A, Gillies C, Ekezie W, Welford A, Zhang A, et al. The prevalence and long-term health effects of Long Covid among hospitalised and non-hospitalised populations: A systematic review and meta-analysis. *EClinicalMedicine*. 2023;55:101762. Epub 2022/12/08. doi: 10.1016/j.eclinm.2022.101762. PubMed PMID: 36474804; PubMed Central PMCID: PMC9714474.
8. Global Burden of Disease Long CC, Wulf Hanson S, Abbafati C, Aerts JG, Al-Aly Z, Ashbaugh C, et al. Estimated Global Proportions of Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic COVID-19 in 2020 and 2021. *JAMA*. 2022;328(16):1604-15. doi: 10.1001/jama.2022.18931. PubMed PMID: 36215063; PubMed Central PMCID: PMC9552043.
9. Nasserie T, Hittle M, Goodman SN. Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19: A Systematic Review. *JAMA Netw Open*. 2021;4(5):e2111417. Epub 2021/05/27. doi: 10.1001/jamanetworkopen.2021.11417. PubMed PMID: 34037731.
10. Castanares-Zapatero D, Chalon P, Kohn L, Dauvrin M, Detollenaere J, Maertens de Noordhout C, et al. Pathophysiology and mechanism of long COVID: a comprehensive review. *Annals of medicine*. 2022;54(1):1473-87. Epub 2022/05/21. doi: 10.1080/07853890.2022.2076901. PubMed PMID: 35594336; PubMed Central PMCID: PMC9132392.
11. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. *Nat Rev Microbiol*. 2023;21(3):133-46. Epub 2023/01/14. doi:

- 10.1038/s41579-022-00846-2. PubMed PMID: 36639608; PubMed Central PMCID: PMC9839201.
12. Buonsenso D, Piazza M, Boner AL, Bellanti JA. Long COVID: A proposed hypothesis-driven model of viral persistence for the pathophysiology of the syndrome. *Allergy Asthma Proc.* 2022;43(3):187-93. doi: 10.2500/aap.2022.43.220018. PubMed PMID: 35524358; PubMed Central PMCID: PMC9106095.
13. Stein SR, Ramelli SC, Grazioli A, Chung JY, Singh M, Yinda CK, et al. SARS-CoV-2 infection and persistence in the human body and brain at autopsy. *Nature.* 2022;612(7941):758-63. Epub 20221214. doi: 10.1038/s41586-022-05542-y. PubMed PMID: 36517603; PubMed Central PMCID: PMC9749650.
14. Swank Z, Senussi Y, Manickas-Hill Z, Yu XG, Li JZ, Alter G, et al. Persistent Circulating Severe Acute Respiratory Syndrome Coronavirus 2 Spike Is Associated With Post-acute Coronavirus Disease 2019 Sequelae. *Clin Infect Dis.* 2023;76(3):e487-e90. doi: 10.1093/cid/ciac722. PubMed PMID: 36052466.
15. Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of antibody immunity to SARS-CoV-2. *Nature.* 2021;591(7851):639-44. Epub 20210118. doi: 10.1038/s41586-021-03207-w. PubMed PMID: 33461210; PubMed Central PMCID: PMC8221082.
16. Peluso MJ, Deeks SG, Mustapic M, Kapogiannis D, Henrich TJ, Lu S, et al. SARS-CoV-2 and Mitochondrial Proteins in Neural-Derived Exosomes of COVID-19. *Ann Neurol.* 2022;91(6):772-81. Epub 20220330. doi: 10.1002/ana.26350. PubMed PMID: 35285072; PubMed Central PMCID: PMC9082480.
17. Su Y, Yuan D, Chen DG, Ng RH, Wang K, Choi J, et al. Multiple early factors anticipate post-acute COVID-19 sequelae. *Cell.* 2022;185(5):881-95 e20. Epub 20220125. doi: 10.1016/j.cell.2022.01.014. PubMed PMID: 35216672; PubMed Central PMCID: PMC8786632.
18. Ambrosino P, Sanduzzi Zamparelli S, Mosella M, Formisano R, Molino A, Spedicato GA, et al. Clinical assessment of endothelial function in convalescent COVID-19 patients: a meta-analysis with meta-regressions. *Annals of medicine.* 2022;54(1):3234-49. doi: 10.1080/07853890.2022.2136403. PubMed PMID: 36382632; PubMed Central PMCID: PMC9673781.
19. Pretorius E, Vlok M, Venter C, Bezuidenhout JA, Laubscher GJ, Steenkamp J, et al. Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. *Cardiovasc Diabetol.* 2021;20(1):172. Epub 20210823. doi: 10.1186/s12933-021-01359-7. PubMed PMID: 34425843; PubMed Central PMCID: PMC8381139.
20. Pretorius E, Venter C, Laubscher GJ, Kotze MJ, Oladejo SO, Watson LR, et al. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC). *Cardiovasc Diabetol.* 2022;21(1):148. Epub 20220806. doi: 10.1186/s12933-022-01579-5. PubMed PMID: 35933347; PubMed Central PMCID: PMC9356426.
21. Ahamed J, Laurence J. Long COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches. *J Clin Invest.* 2022;132(15). doi: 10.1172/JCI161167. PubMed PMID: 35912863; PubMed Central PMCID: PMC9337829.
22. Weidman K, LaFond E, Hoffman KL, Goyal P, Parkhurst CN, Derry-Vick H, et al. Post-Intensive Care Unit Syndrome in a Cohort of COVID-19 Survivors in New York City. *Ann Am Thorac Soc.* 2022;19(7):1158-68. doi: 10.1513/AnnalsATS.202104-520OC. PubMed PMID: 34936536; PubMed Central PMCID: PMC9278639.
23. Tipirdamaz C, Zayet S, Osman M, Mercier J, Bouvier E, Gendrin V, et al. Asthma and Cacosmia Could Be Predictive Factors of Olfactory Dysfunction Persistence 9 Months after

- SARS-CoV-2 Infection: The ANOSVID Study. *Life (Basel)*. 2022;12(7). Epub 20220621. doi: 10.3390/life12070929. PubMed PMID: 35888019; PubMed Central PMCID: PMC9319724.
24. Schultheiss C, Willscher E, Paschold L, Gottschick C, Klee B, Bosurgi L, et al. Liquid biomarkers of macrophage dysregulation and circulating spike protein illustrate the biological heterogeneity in patients with post-acute sequelae of COVID-19. *J Med Virol*. 2023;95(1):e28364. doi: 10.1002/jmv.28364. PubMed PMID: 36458566; PubMed Central PMCID: PMC9878213.
25. Cheon IS, Li C, Son YM, Goplen NP, Wu Y, Cassmann T, et al. Immune signatures underlying post-acute COVID-19 lung sequelae. *Sci Immunol*. 2021;6(65):eabk1741. Epub 20211112. doi: 10.1126/sciimmunol.abk1741. PubMed PMID: 34591653; PubMed Central PMCID: PMC8763087.
26. Vijayakumar B, Boustani K, Ogger PP, Papadaki A, Tonkin J, Orton CM, et al. Immuno-proteomic profiling reveals aberrant immune cell regulation in the airways of individuals with ongoing post-COVID-19 respiratory disease. *Immunity*. 2022;55(3):542-56 e5. Epub 20220126. doi: 10.1016/j.immuni.2022.01.017. PubMed PMID: 35151371; PubMed Central PMCID: PMC8789571.
27. Patterson BK, Francisco EB, Yogendra R, Long E, Pise A, Rodrigues H, et al. Persistence of SARS CoV-2 S1 Protein in CD16+ Monocytes in Post-Acute Sequelae of COVID-19 (PASC) up to 15 Months Post-Infection. *Front Immunol*. 2021;12:746021. Epub 20220110. doi: 10.3389/fimmu.2021.746021. PubMed PMID: 35082777; PubMed Central PMCID: PMC8784688.
28. Littlefield KM, Watson RO, Schneider JM, Neff CP, Yamada E, Zhang M, et al. SARS-CoV-2-specific T cells associate with inflammation and reduced lung function in pulmonary post-acute sequelae of SARS-CoV-2. *PLoS Pathog*. 2022;18(5):e1010359. Epub 20220526. doi: 10.1371/journal.ppat.1010359. PubMed PMID: 35617421; PubMed Central PMCID: PMC9176759.
29. Ong SWX, Fong SW, Young BE, Chan YH, Lee B, Amrun SN, et al. Persistent Symptoms and Association With Inflammatory Cytokine Signatures in Recovered Coronavirus Disease 2019 Patients. *Open Forum Infect Dis*. 2021;8(6):ofab156. Epub 20210402. doi: 10.1093/ofid/ofab156. PubMed PMID: 34095336; PubMed Central PMCID: PMC8083585.
30. Phetsouphanh C, Darley DR, Wilson DB, Howe A, Munier CML, Patel SK, et al. Immunological dysfunction persists for 8 months following initial mild-to-moderate SARS-CoV-2 infection. *Nat Immunol*. 2022;23(2):210-6. Epub 20220113. doi: 10.1038/s41590-021-01113-x. PubMed PMID: 35027728.
31. Peluso MJ, Lu S, Tang AF, Durstenfeld MS, Ho HE, Goldberg SA, et al. Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *J Infect Dis*. 2021;224(11):1839-48. doi: 10.1093/infdis/jiab490. PubMed PMID: 34677601; PubMed Central PMCID: PMC8643408.
32. Gold JE, Okyay RA, Licht WE, Hurley DJ. Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation. *Pathogens*. 2021;10(6). Epub 2021/07/03. doi: 10.3390/pathogens10060763. PubMed PMID: 34204243; PubMed Central PMCID: PMC8233978.
33. Peluso MJ, Deveau TM, Munter SE, Ryder D, Buck A, Beck-Engeser G, et al. Chronic viral coinfections differentially affect the likelihood of developing long COVID. *J Clin Invest*. 2023;133(3). Epub 20230201. doi: 10.1172/JCI163669. PubMed PMID: 36454631; PubMed Central PMCID: PMC9888380.
34. Liu Q, Mak JWY, Su Q, Yeoh YK, Lui GC, Ng SSS, et al. Gut microbiota dynamics in a prospective cohort of patients with post-acute COVID-19 syndrome. *Gut*. 2022;71(3):544-52. Epub 2022/01/28. doi: 10.1136/gutjnl-2021-325989. PubMed PMID: 35082169; PubMed Central PMCID: PMC8814432.

35. Giron LB, Peluso MJ, Ding J, Kenny G, Zilberstein NF, Koshy J, et al. Markers of fungal translocation are elevated during post-acute sequelae of SARS-CoV-2 and induce NF-kappaB signaling. *JCI Insight*. 2022;7(15). Epub 2022/06/22. doi: 10.1172/jci.insight.160989. PubMed PMID: 35727635; PubMed Central PMCID: PMCPMC9462470.
36. Zupo R, Castellana F, Sardone R, Sila A, Giagulli VA, Triggiani V, et al. Preliminary Trajectories in Dietary Behaviors during the COVID-19 Pandemic: A Public Health Call to Action to Face Obesity. *Int J Environ Res Public Health*. 2020;17(19). Epub 2020/10/01. doi: 10.3390/ijerph17197073. PubMed PMID: 32992623; PubMed Central PMCID: PMCPMC7579065.
37. Brenan M. American's Mental Health Ratings Sink to New Low 2020 [cited 2021 Jan 14]. Available from: <https://news.gallup.com/poll/327311/americans-mental-health-ratings-sink-new-low.aspx>.
38. Czeisler ME, Marynak K, Clarke KEN, Salah Z, Shakya I, Thierry JM, et al. Delay or Avoidance of Medical Care Because of COVID-19-Related Concerns - United States, June 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(36):1250-7. Epub 2020/09/12. doi: 10.15585/mmwr.mm6936a4. PubMed PMID: 32915166; PubMed Central PMCID: PMCPMC7499838.
39. Metz TD, Clifton RG, Gallagher R, Gross RS, Horwitz LI, Jacoby VL, et al. Researching COVID to enhance recovery (RECOVER) pregnancy study: Rationale, objectives and design. *medRxiv*. 2023:2023.04.24.23289025. doi: 10.1101/2023.04.24.23289025.
40. RECOVER. RECOVER Leadership 2023 [cited 2023 3 Feb 2023]. Available from: <https://recovercovid.org/leadership>.
41. World Health Organization. WHO COVID-19 Case definition 2021 [cited 2023 3 Feb 2023]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Surveillance_Case_Definition-2022.1.
42. Centers for Disease Control and Prevention. Demographic Trends of COVID-19 cases and deaths in the US reported to CDC 2021 [cited 2023 3 Feb 2023]. Available from: <https://covid.cdc.gov/covid-data-tracker/#demographics>.
43. National Institute of Standards and Technology CSRC. NIST Risk Management Framework 2022 [cited 2023 3 Feb 2023]. Available from: <https://csrc.nist.gov/projects/risk-management>.
44. Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O'Neal L, et al. The REDCap consortium: Building an international community of software platform partners. *Journal of biomedical informatics*. 2019;95:103208. Epub 20190509. doi: 10.1016/j.jbi.2019.103208. PubMed PMID: 31078660; PubMed Central PMCID: PMCPMC7254481.
45. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. *Journal of biomedical informatics*. 2009;42(2):377-81. Epub 20080930. doi: 10.1016/j.jbi.2008.08.010. PubMed PMID: 18929686; PubMed Central PMCID: PMCPMC2700030.
46. Tibshirani R. Regression shrinkage and selection via the lasso. *Journal of the Royal Statistical Society: Series B*. 1996;58(1):267-88.
47. Chattopadhyay A, Hase CH, Zubizarreta JR. Balancing vs modeling approaches to weighting in practice. *Stat Med*. 2020;39(24):3227-54. Epub 20200903. doi: 10.1002/sim.8659. PubMed PMID: 32882755.
48. Monti S, Tamayo P, Mesirov J, Golub T. Consensus Clustering: A Resampling-Based Method for Class Discovery and Visualization of Gene Expression Microarray Data. *Machine Learning*. 2003;52(1):91-118. doi: 10.1023/A:1023949509487.
49. Fine JP, RJ G. A proportional hazards model for the subdistribution of a competing risk. *J Am Stat Assoc*. 1999;94:496-509.

50. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. *Epidemiology*. 2000;11(5):550-60. doi: 10.1097/00001648-200009000-00011. PubMed PMID: 10955408.
51. National Institutes of Health. Scientific Data Sharing 2023 [cited 2023 3 Feb 2023]. Available from: <https://sharing.nih.gov/data-management-and-sharing-policy/planning-and-budgeting-for-data-management-and-sharing/writing-a-data-management-and-sharing-plan#before>.
52. Prevention CfDCa. Clinical Laboratory Improvement Amendments (CLIA). 2018 [cited 2023 3 Feb 2023]. Available from: <https://www.cdc.gov/clia/about.html>.
53. FAIR Health. A detailed study of patients with long-haul COVID: An analysis of private healthcare claims. 2021 June 15. Report No.
54. Naik S, Haldar SN, Soneja M, Mundadan NG, Garg P, Mittal A, et al. Post COVID-19 sequelae: A prospective observational study from Northern India. *Drug Discov Ther*. 2021;15(5):254-60. Epub 20211030. doi: 10.5582/dtd.2021.01093. PubMed PMID: 34719599.
55. Larsen NW, Stiles LE, Shaik R, Schneider L, Muppidi S, Tsui CT, et al. Characterization of autonomic symptom burden in long COVID: A global survey of 2,314 adults. *Front Neurol*. 2022;13:1012668. Epub 20221019. doi: 10.3389/fneur.2022.1012668. PubMed PMID: 36353127; PubMed Central PMCID: PMC9639503.
56. Huang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. *Lancet*. 2021;397(10270):220-32. Epub 2021/01/12. doi: 10.1016/S0140-6736(20)32656-8. PubMed PMID: 33428867; PubMed Central PMCID: PMC9639503.
57. Sorensen AIV, Spiliopoulos L, Bager P, Nielsen NM, Hansen JV, Koch A, et al. A nationwide questionnaire study of post-acute symptoms and health problems after SARS-CoV-2 infection in Denmark. *Nat Commun*. 2022;13(1):4213. Epub 20220721. doi: 10.1038/s41467-022-31897-x. PubMed PMID: 35864108; PubMed Central PMCID: PMC9302226.
58. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. *Nature*. 2021. Epub 2021/04/23. doi: 10.1038/s41586-021-03553-9. PubMed PMID: 33887749.
59. Horberg MA, Watson E, Bhatia M, Jefferson C, Certa JM, Kim S, et al. Post-acute sequelae of SARS-CoV-2 with clinical condition definitions and comparison in a matched cohort. *Nat Commun*. 2022;13(1):5822. Epub 20221012. doi: 10.1038/s41467-022-33573-6. PubMed PMID: 36224218; PubMed Central PMCID: PMC9556630.
60. Mizrahi B, Sudry T, Flaks-Manov N, Yehezkeli Y, Kalkstein N, Akiva P, et al. Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. *Bmj*. 2023;380:e072529. Epub 20230111. doi: 10.1136/bmj-2022-072529. PubMed PMID: 36631153; PubMed Central PMCID: PMC9832503.
61. Reese JT, Blau H, Casiraghi E, Bergquist T, Loomba JJ, Callahan TJ, et al. Generalisable long COVID subtypes: findings from the NIH N3C and RECOVER programmes. *EBioMedicine*. 2023;87:104413. Epub 20221221. doi: 10.1016/j.ebiom.2022.104413. PubMed PMID: 36563487; PubMed Central PMCID: PMC9769411.
62. Roessler M, Tesch F, Batram M, Jacob J, Loser F, Weidinger O, et al. Post-COVID-19-associated morbidity in children, adolescents, and adults: A matched cohort study including more than 157,000 individuals with COVID-19 in Germany. *PLoS Med*. 2022;19(11):e1004122. Epub 20221110. doi: 10.1371/journal.pmed.1004122. PubMed PMID: 36355754; PubMed Central PMCID: PMC9648706.

Supporting information

S1 Fig: Protocol Development Timeline

S2 Fig: RECOVER Consortium Oversight Structure

S1 Table: Hubs and Enrolling Sites

S2 Table: Survey Topics as of Protocol Version 7.0

S3 Table: Tier 1 Assessments

S4 Table: Tier 2 Assessments

S5 Table: Tier 3 Assessments

S6 Table: Writing Committee

S7 Table: RECOVER-Adult Consortium Members

S8 Table: RECOVER-Adult Committees and Task Forces

Workflow for Acute and Post-Acute

Legend

- Completed by research coordinator
- Completed by participant
- Completed by research coordinator with review/validation by participant

eCRF	Baseline	Time Point after index date															
		3m	6m	9m	12m	15m	18m	21m	24m	27m	30m	33m	36m	39m	42m	45m	48m
Enrollment	●																
Tier 1-2 Consent	●																
Identity	●																
Visit	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Comorbidities	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
COVID Treatment*	●																
Medications	●																
Change in Medications		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Demographics	●																
PASC Symptoms	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Vaccination Status	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Social Determinants of Health	●																
Social Determinants Follow-up		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Alcohol/Tobacco	●																
Alcohol/Tobacco Follow-up		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Disability	●																
Pregnancy	●																
Pregnancy Follow-up		●	●	●	●	●	●	●	●	●	●	●	●	●	●	●	●
Tier 1 office visit	●		●		●				●			●					●
Biospecimens	●	●	●		●				●			●					●
Lab Results	●	●	●		●				●			●					●
Tier 2/Tier 3 Tests		●															

* COVID Treatment not collected on people without infection

